Lilly’s Mounjaro more popular than Wegovy in UK’s private obesity drug market
By Maggie Fick LONDON (Reuters) – Britons paying privately for obesity drugs are increasingly choosing Eli Lilly’s Mounjaro over Novo Nordisk’s Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its European rival. Mounjaro is appealing to people because of its greater efficacy, six online pharmacies and two patients told …
Lilly’s Mounjaro more popular than Wegovy in UK’s private obesity drug market Read More »










